<DOC>
	<DOC>NCT00372957</DOC>
	<brief_summary>To investigate the preliminary pharmacokinetics, pharmacodynamics, safety and tolerability of GW823093 at doses of 15mg and 30mg given once daily for 7 days in Japanese Type 2 diabetes mellitus (T2DM) patients.</brief_summary>
	<brief_title>Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Inclusion criteria: T2DM diagnosed at least 3 months prior to Screening and fasting plasma glucose (FPG) level &lt;280mg/dL at the Screening visit. Concurrent T2DM therapy: Must be diet controlled OR not taking more than 2 oral antidiabetic agents, and willing to withdraw from these treatments 2 weeks prior to the first dosing. Exclusion criteria: Must not have any other major illness other than diabetes</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>